Gujarat Alkalies Q2 FY27 Results Due November 5

Gujarat Alkalies and Chemicals Limited will consider its unaudited standalone and consolidated Q2 FY27 and half-year results on November 5, 2026, after reporting ₹1,245 crore revenue and ₹55 crore net profit for the June 2026 quarter. The board meeting is the next scheduled financial disclosure for investors tracking the chemical manufacturer.

When will Gujarat Alkalies release Q2 FY27 results?

Gujarat Alkalies and Chemicals Limited, referred to as GACL, has scheduled a board meeting for Thursday, November 5, 2026, to consider and approve unaudited provisional financial results for the second quarter and half year ended September 30, 2026. The company disclosed the meeting schedule under Regulation 29(1)(a) of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

The corporate-action calendar also lists November 5 as the date for the Q2 FY26-27 stock result. This follows the company’s first-quarter earnings date of July 23, 2026. The available information does not provide the Q2 financial figures ahead of the board meeting, so the scheduled event should not be treated as a reported earnings outcome.

GACL said its trading window closed on October 1, 2026, and will remain shut until November 7, 2026. The closure covers the period around the board meeting at which provisional Q2 and first-half results are due to be considered.

What did GACL report in the June 2026 quarter?

GACL reported revenue of ₹1,245 crore and net profit of ₹55 crore for the quarter ended June 30, 2026. Revenue rose 12.7% from ₹1,105 crore in the corresponding quarter a year earlier, while the company moved from a net loss of ₹14 crore in the earlier period to a profit.

Earnings per share for the June 2026 quarter were ₹7.49. The operating margin was reported at 18.0% as of November 2, 2026, which was 9.0 percentage points higher than a year earlier. The provided financial summary separately shows revenue of ₹1,244 crore, gross profit of ₹118 crore and net profit of ₹53 crore, indicating a small difference between summary-page metrics and the quarterly results data.

The quarterly results data also shows revenue growth of 10.63% quarter on quarter and 12.65% year on year. Gross profit was stated to have increased 2,099.44% quarter on quarter and 703.73% year on year, while net profit increased 573.39% quarter on quarter and 585.49% year on year. These percentage comparisons should be read alongside the low or negative profit base in the preceding periods.

Which financial figures should investors track before the Q2 update?

Investors can use the June-quarter revenue, profit and margin figures as the most recent disclosed operating reference before GACL’s November 5 board meeting. The company manufactures and markets chemical products in India, making reported sales, operating profitability and earnings per share relevant indicators in the forthcoming disclosure.

The source also refers to an analyst and institutional investor meeting with HSBC Securities and Capital Markets (India) Pvt. However, no details of the discussion, guidance or investor presentation were provided. GACL has also disclosed credit-rating reports issued by CARE Ratings Limited, though the supplied material does not state the ratings or their rationale.

Why is the November 5 board meeting important for GACL shareholders?

The November 5 meeting is important because it will provide GACL’s next formal update on standalone and consolidated financial performance for the quarter and first half ended September 30. The June quarter had shown higher revenue and a return to profitability compared with the year-earlier loss, making the next set of reported figures a key update on the company’s recent financial trajectory.

The provided record contains reports from earlier periods that should not be confused with the pending Q2 FY27 announcement. One item says GACL previously reported Q2 revenue of ₹1,907.32 crore and made a ₹1,549.24 crore provision for goods damaged in a fire at contractor Sanghvi Organics’ facility. The source does not specify the period for that item, and it is not presented as the upcoming November 2026 result.

Another historical update referred to Q2 FY2025-26 sales revenue of ₹1,063 crore, up 10%, EBITDA of ₹133 crore, and profit before tax of ₹13 crore. It also said first-half EBITDA increased 28% to ₹258 crore, citing production, sales realisation and energy-cost factors. Those figures provide historical context but are not comparable with an unreported Q2 FY27 result without the company’s forthcoming financial statements.

How do these disclosures affect the chemicals business outlook?

The available disclosures show that GACL’s latest reported June-quarter performance included year-on-year revenue growth, an improvement in operating margin and a return to net profit. For a chemical producer, these reported measures help investors assess the relationship between sales growth and operating profitability, but they do not establish the September-quarter outcome before the board approves it.

The trading-window closure is a standard governance measure intended to restrict dealing by designated persons while they may possess unpublished price-sensitive information. The pending results, rather than an intraperiod share-price claim, are the central disclosed market event. No current share price, price movement, dividend decision or forecast was included in the supplied material.

GACL’s disclosures also include a registrar certificate from MUFG Intime India Private Limited confirming proper dematerialisation processes and regulatory compliance for the quarter ended March 31, 2026. This is separate from operating performance, but it records a compliance-related corporate update ahead of the November earnings event.

Conclusion

GACL’s scheduled November 5 board meeting will deliver the company’s Q2 FY27 and first-half financial update. The June quarter set the immediate reference point, with ₹1,245 crore revenue, ₹55 crore net profit, ₹7.49 earnings per share and an 18.0% operating margin.

The next item to watch is the board-approved standalone and consolidated results for the quarter and half year ended September 30, 2026. Investors can also monitor disclosures following the scheduled meeting, including any information arising from the company’s analyst and institutional investor engagement.